GALWAY, Ireland, Oct. 22, 2025 /PRNewswire/ -- Neurent Medical, a leader in non-surgical treatments for chronic rhinitis, today announced that UnitedHealthcare's Medicare Advantage policy has removed ...
76% of participants achieved the responder rate (≥30% reduction in rTNSS). 91% achieved the minimum clinically important difference (MCID) of ≥1 point reduction in rTNSS. All 4 rTNSS subscores ...
Neurent Medical has closed an oversubscribed Series C financing round, raising €62.5m ($74m) to expand commercial activities for the NEUROMARK system targeting chronic rhinitis, generate additional ...
GALWAY, Ireland--(BUSINESS WIRE)--Neurent Medical, a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, today announced three-month data from ...
GALWAY, Ireland, Feb. 24, 2026 /PRNewswire/ -- Neurent Medical, a leader in non-surgical treatments for chronic rhinitis, today announced the publication of positive results from its randomized ...
Galway-headquartered Neurent Medical, a leader in pioneering non-surgical solutions for chronic sinonasal inflammatory diseases, announced that the US Food and Drug Administration (FDA) has granted ...
GALWAY, Ireland and BRAINTREE, Mass., Feb. 11, 2026 /PRNewswire/ -- Neurent Medical, the pioneer behind NEUROMARK®, an innovative, minimally invasive solution to treat chronic rhinitis, today ...
Proprietary NEUROMARK system is the first in-office treatment indicated to disrupt symptom-causing nerve tissue for Chronic Rhinitis patients. Neurent Medical, a company pioneering innovative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results